Charcot-Marie-Tooth Disease Type 1A Clinical Trials

14 clinical trials for Charcot-Marie-Tooth Disease Type 1A across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A — RECRUITING · NA
• A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A. — RECRUITING · PHASE1
• Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter) — RECRUITING · PHASE1
• A FIRST-IN-HUMAN, MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF EDK060 IN ADULTS WITH CHARCOT-MARIE TOOTH TYPE 1A (CMT1A) — RECRUITING
• Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease — RECRUITING · NA
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFECTS OF ACE-083 IN PATIENTS WITH FSHD PREVIOUSLY ENROLLED IN STUDY A083-02 AND IN PATIENTS WITH CMT DISEASE TYPES 1 AND X PREVIOUSLY ENROLLED IN STUDY A083-03 — RECRUITING
• INTERNATIONAL, MULTI-CENTER, DOUBLE BLIND 9-MONTH FOLLOW-UP EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND TOLERABILITY OF PXT3003 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A — RECRUITING
• LONG TERM EFFECT AND TOLERANCE OF ULIPRISTAL ACETATE IN Charcot-Marie-TOOTH DISEASE TYPE 1A (UPACOMT) — COMPLETED · PHASE2
• International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months — COMPLETED · PHASE3
• Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers — ACTIVE_NOT_RECRUITING · NA
• A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PXT3003 IN CHARCOT- MARIE-TOOTH TYPE 1A (CMT1A) — COMPLETED · PHASE3
• SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study — COMPLETED · PHASE2
• Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) — COMPLETED · PHASE3
• Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) — OTHER · PHASE2

Refine this search